Cyclovirobuxin D(Bebuxine)

Cyclobenzaprine Hcl is a skeletal muscle relaxant and a central nervous system (CNS) depressant.

Cyclo (RGDfC), avb3 Integrin Binding Cyclic RGD Peptide,This is a cyclic RGDfC sequence, an integrin avb3-affine peptide.

CW-069 is a novel and allosteric inhibitor of the microtubule motor protein HSET with IC50 value of 75 ± 20 μM; shows statistically significant selectivity over KSP.

CTX-0294885 is a novel broad-spectrum kinase inhibitor.

CTPI-2 (SLC25A1 inhibitor CTPI-2) is a novel specific SLC25A1 inhibitor with Kd of 3.5 uM, CTPI-2 is synthetic lethal with cisplatin or with EGFR inhibitor co-treatment and restores antitumor responses both in vitro and in vivo; disrupts self-renewal and

CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apo

CPI-169 R is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2.

CPHPC(GSK2315698,Miridesap) is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance.

Cordycepin is an adenosine analogue, which is readily phosphorylated to its mono-, di-, and triphosphate intracellularly. It has a very potent anti-cancer, anti-oxidant and anti-inflammatory activities.

Coenzyme Q9, a nine isoprenyl group-containing member of the ubiquinone family, is a normal constituent of human plasma.

CNV1014802 (GSK-1014802, Raxatrigine, Vixotrigine, BIIB074) is a potent, selective Nav1.7 sodium channel blocker, shows analgesic effects and potential in the treatment of cognitive symptoms of schizophrenia in vivo.

CNDAC (DFP-10917; TAS-109) is an orally available deoxycytosine nucleoside analog with potential antineoplastic activity.

Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. IC50 Value: 65 nM Target: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. It

Citarinostat(ACY-241) is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.

Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

CID-797718 is a compound with unknown details.

CID-2011756 is a cell-active ATP competitive and specific PKD1 inhibitor that inhibits phorbol ester-induced endogenous PKD1 activation in LNCaP prostate cancer cells.

CHIR-090 is a potent LpxC inhibitor, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin or tobramycin.

CGP 71683A is a potent and highly selective non-peptide antagonist of the NPY Y(5) receptor in the study of obesity.

CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.

Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.

CDDO is a synthetic oleanane triterpenoid that blocks the cellular synthesis of inducible nitric oxide synthase and inducible COX-2 in INF-γ-activated mouse macrophages with an IC50 value of 0.4 nM.

CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38.

CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR).

CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.

CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.

CCF642 is a novel protein disulfide isomerases (PDI) inhibitor.

CCDC is a otent, selective TGR5 G-protein coupled receptor agonist (pEC50 = 6.8).